Harrow (HROW) Stock Forecast: StockMap's 2-Week Call

HROW stock forecast: StockMap's model leans Underperform on Harrow for the two weeks after the Nov 13 close, toward HROW trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Too few two-week windows graded to judge yet.

Harrow last closed at $30.12, +6.43% on the session.

Against the IVW growth benchmark the position is +7.34% over the forecast window.

Harrow's market cap is $1.13B as of November 13, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -45 (too close to call).

Where HROW sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

15 daily calls for HROW so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Harrow in the 12th percentile on return on equity, where 100 is best.

Harrow is classified under Health Care / Pharmaceuticals.

StockMap tracks Harrow as the 64th largest of the 152 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 73 Moderate Underperform, 49 Neutral and 30 Strong Underperform.

On that composite Harrow ranks 111th of 152 in the group, against a group median of -0.33.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 13, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Harrow (HROW) — StockMap 2-week forecast & tracked accuracy